ArticleBMC biotechnology2025
Online monitoring of the mitochondrial respiration activity and protein formation in the Almost Living Cell-free Expression (ALiCE) system.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Eukaryotic cell-free protein synthesis: Chassis diversification, system engineering, and emerging applications.Synthetic and systems biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCell-free protein synthesis (CFPS) is one approach to address the increasing demand for complex recombinant proteins in various applications, especially in the pharmaceutical sector. CFPS offers a variety of advantages like the ability to express cytotoxic proteins, no need for transformations or screening of strains and, thus, reduced production times. Often industrially relevant proteins require post-translational modifications (PTM). While disulfide bonds can be obtained with prokaryotic systems, some eukaryotic CFPS systems are able to perform glycosylation to a limited extent. However, scaling the production of a eukaryotic CFPS system and protein production has been a main challenge to enable the manufacturing of complex proteins with these CFPSs. One plant-based system that overcomes these limitations is the Almost Living Cell-free Expression (ALiCE) system, which is based on tobacco BY-2 cells and can produce protein titers of up to 3 µg/µL in batch mode. This study focuses on gaining a deeper understanding of oxygen demand, protein formation and the role of mitochondria in this CFPS system.
resultsOnline monitoring was established in a combined µRAMOS-BioLector device to investigate the correlation of oxygen transfer, eYFP production and NADH levels during the ALiCE reaction. By varying the maximum oxygen transfer capacity, it was revealed that oxygen availability is tightly coupled to protein formation and that the eYFP production rate decreases with decreasing oxygen availability. Moreover, the mitochondrial inhibitors salicylhydroxamic acid (SHAM) and potassium cyanide (KCN) were added to ALiCE reactions to examine the influence and importance of mitochondrial alternative oxidase and cytochrome c oxidase on the ALiCE reaction. Inhibition of alternative oxidase and cytochrome c oxidase demonstrated that oxygen is consumed in the respiratory chain of intact mitochondria within the ALiCE system. In addition, the NADH balance and eYFP formation are highly dependent on oxygen availability.
conclusionsFor the first time, a plant-based cell-free expression system was characterized concerning oxygen demand and the influence of oxygen availability on the kinetics of protein production. The new findings enable the design of ALiCE experiments in mL-scale with optimal oxygen supply for protein formation in the future and provide first insights into the energy metabolism of this plant-based CFPS system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.